Recorded at the 67th American Society of Hematology Annual Meeting and Exposition, Jean-Marie Michot, MD, of Institut Gustave Roussy in France, discusses the ASH abstract titled “Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study.”
The phase 3 trial evaluated the safety and efficacy of odronextamab, a CD20xCD3 bispecific antibody, in combination with CHOP chemotherapy for patients with previously untreated DLBCL.
Reference
Michot J-M, Yagci M, Kargus K, et al. Odronextamab plus chemotherapy in patients with previously untreated diffuse large B-cell lymphoma (DLBCL): First Results from part 1 of the Phase 3 Olympia-3 study. Abstract #abs25-8890. 67th American Society of Hematology Annual Meeting and Exposition. December 6–9; Orlando, Florida.
